Communiqués Ironwood Pharmaceuticals, Inc. Börse Stuttgart

Actions

I76

US46333X1081

Produits pharmaceutiques

Temps réel estimé Tradegate 15:36:31 14/08/2026			Varia. 5j.	Varia. 1 janv.
3,460 ^EUR	-1,14%		-4,37%	+31,58%

06/08	Transcript : Ironwood Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
06/08	Ironwood Pharmaceuticals, Inc. relève ses prévisions de résultats pour l'exercice 2026	CI

Communiqués

07/08	Ironwood Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Ironwood: Q2 Earnings Snapshot	AQ
06/08	Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results	BU
30/07	Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call	BU
15/07	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development, STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients	AQ
14/07	Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients	BU
28/05	Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference	BU
27/05	FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)	BU
08/05	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth, Maintains Full-Year 2026 Financial Guidance	AQ
08/05	Ironwood Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Ironwood Pharmaceuticals : Q1 2026 Update	PU
07/05	Ironwood: Q1 Earnings Snapshot	AQ
07/05	Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance	BU
04/05	Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)	BU
30/04	Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call	BU
23/04	Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026	BU
04/03	Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference	BU
25/02	Ironwood: Q4 Earnings Snapshot	AQ
25/02	Ironwood Pharmaceuticals : Fourth Quarter 2025 Ironwood 4Q 2025 Investor Update	PU
25/02	Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook	BU
18/02	Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call	BU
02/01	Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance	BU
13/11	Ironwood Pharmaceuticals : Third Quarter 2025 Ironwood 3Q 2025 Update	PU
10/11	Ironwood: Q3 Earnings Snapshot	AQ
10/11	Ironwood Pharmaceuticals : Q3 2025 Update	PU